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The phentermine, an appetite suppressant, has been
widely applied in Korea since 2004. However, there have
been relatively few reports about the efficacy and the safety
of phentermine in Korea. The aim of this study is to verify
the effect of phentermine on weight reduction and the safety
in Korean patients. This randomized, double-blind, placebo-
controlled study had been performed between February and
July, 2005, in Seoul on 68 relatively healthy obese adults
whose body mass index was 25 kg/m2 or greater. They
received phentermine-HCl 37.5 mg or placebo once daily
with behavioral therapy for obesity. The primary endpoints
were the changes of body weight and waist circumference
from the baseline in the intention-to-treat population. Mean
decrease of both body weight and waist circumference in
phentermine-treated subjects were significantly greater than
that of placebo group (weight: -6.7 ± 2.5 kg, p < 0.001;
waist circumference: -6.2 ± 3.5 cm, p < 0.001). Significant
number of subjects in phentermine group accomplished
weight reduction of 5% or greater from the baseline and
10% or more (p < 0.001). There were no significant differ-
ences in systolic and diastolic blood pressure between the
groups (p = 0.122 for systolic BP; p = 0.219 for diastolic
BP). Dry mouth and insomnia were the only statistically
significant adverse events that occurred more frequently in
phentermine group. Most side effects of phentermine were
mild to moderate in intensity. Short-term phentermine
administration induced significant weight reduction and
reduction of waist circumference without clinically pro-
blematic adverse events on relatively healthy Korean obese
people.
Key Words: Obesity, phentermine, treatment outcome
INTRODUCTION
Obesity, characterized by the excess accumula-
tion of fat in body, is a chronic disease which is
induced by many causes and needs long-term
management. Obesity prevails all over the world.
Moreover, obesity leads to the increase of several
co-morbidities and all-cause mortality, and pro-
duces extreme economic losses for management
of the obesity-related diseases.1-4 The situation is
same in Korea. The obese population [body mass
index (BMI) 25 kg/m2] rate of Korea has
soared by 12.6%, from 23.3% in 1992 to 35.9% in
2000.5
Several methods have been tried in order to
prevent and treat the increasing rate of obesity
and its related disorders. One of such attempt is
the application of appetite-suppressing drugs,
which is used in many countries for reducing the
energy intake. Among these drugs, phentermine
(Ionamin ) is the drug which had been approved
for short-term use as treatment of obesity by US
FDA in 1959, and has been used steadily until
present. Phentermine, classified as a -pheneβ -
thylamine drug, stimulates the secretion of
noradrenalin in central nervous system, and
noradrenalin, in turn, suppresses appetite by
stimulating the -adrenergic receptors.β
6,7
One of the reasons why phentermine is still
prescribed in the era of appearance of several new
anti-obesity drugs is that it has been administered
safely without serious side effects for the past 40
years in US. However, because of the fact that
phentermine is a sympathomimetic amine, we
should keep in mind the possible side effects of
the drug of this class in using phentermine.
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Although the combination of fenfluramin and
phentermine have been demonstrating a remark-
able weight reduction effect, US FDA has
removed fenfluramin from the market in Septem-
ber 1997, due to the successive reports about the
serious side effects of valvular heart disease and
primary pulmonary hypertension. There have
been scarce reports about serious side effects for
the single use of phentermine; however, there is
a researcher who argued that 15 of 1000
phentermine administered patients might ex-
perience serious side effects.4
Another reason for wide distribution of
phentermine prescription is its low economic
burden for use in contrast to the new drugs.
Comparing the cost-effectiveness of sibutramine
and phentermine, in US, 103.8 $ per month for
sibutramine 10 mg daily induces 4.45 kg weight
reduction in 12 months. On the other hand, 39.59
$ per month for phentermine resin 30 mg daily
induces 3.6 kg weight reduction in 6 months.8
Such data regarding this cost-effectiveness might
be the important criteria for the selection of which
drug to use.
Phentermine has been introduced in Korea
since 2004, and have been prescribed widely. The
reports of the randomized controlled studies of
phentermine had been published from 1975 to
1999, and there have been no further clinical trials
on the phentermine usage since 1999.9 Moreover,
there are few reports about the effect and safety
profile of phentermine in Korean. Therefore, we
performed a double-blind placebo-controlled trial
of phentermine in order to reaffirm the effect of
phentermine on weight reduction and to verify
the safety in Korean obese patients.
MATERIALS AND METHODS
Subjects
The study was conducted in men and women
aged 20 years or older who were obese without
any other documented health problems except
hypertension and dyslipidemia. BMI of individual
subjects were 25 kg/m2 or higher, which is used
as a cutoff point for obesity in the Asia-Pacific re-
gion.10,11 The recruitment had been done between
January and February, 2005, in Seoul, and the
target number of the recruitment was 80.
With respect to hypertension, those subjects,
whose systolic blood pressure was controlled
under 140 mmHg and diastolic pressure was
controlled under 90 mmHg by taking anti-hyper-
tensive drugs except MAO inhibitors and whose
prescription of anti-hypertensives had not been
changed in the last two months, were included.
For dyslipidemia, only the subjects who do not
take any lipid lowering drug were included.
Furthermore, subjects who had not been diag-
nosed as diabetes mellitus and whose fasting
plasma glucose was less than 126 mg/dL without
any diabetic care were included. In addition to the
medication currently under the study, aspirin for
the prevention of cerebrovascular disease and
anti-hypertensives, except MAO inhibitors, were
the only permitted medication during the study
period.
Those subjects who have experienced weight
change by more than 5% of baseline body weight
in several months before the recruitment were
excluded. Pregnant women and breast-feeding
mothers were also excluded. Subjects taking any
type of medication or receiving any kind of
medical treatment during the previous 1 month
prior to enrolment into the study were excluded,
as well. Also excluded were the subjects who had
any other active acute or chronic illnesses, except
hypertension and dyslipidemia, subjects with the
past history of malignancy or eating disorder in
the last five years, subjects who had undergone a
bariatric operation, and subjects who were
regarded as high risk person by researchers'
judgment. Also contraindicated were the subjects
with a history of significant cardiovascular
disease, liver disease, renal disease, drug abuse,
psychiatric conditions, or cataract. Subjects with
an abnormal hematological profile, creatinine
levels and/or thyroid function test were excluded,
too.
Methods
All subjects were briefed on the research pro-
cedures, and a written consent for participation
was obtained from each subject. The Severance
Hospital Institutional Review Board approved this
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study.
The study had been performed between Feb-
ruary and July, 2005. The study was a ran-
domized, double-blind, placebo-controlled study
with the initial screening period and the 14 weeks
of treatment period including 2-week single-blind
placebo run-in period.
During the screening period, subjects who were
determined to their minds to participate in the
study were measured for body weight and height,
and were interviewed to confirm whether they
were appropriate for the study participation. And
then, they visited the researchers with an empty
stomach for more accurate anthropometric mea-
surement and screening laboratory test. According
to the screening test results, final decision whether
the applicant shall be included was made. Sub-
jects who had been permitted for the study
participation were randomized to treatment with
phentermine HCl 37.5 mg once daily or placebo at
Baseline. The ratio for phentermine and placebo
was 1 : 1.
After 2-week placebo run-in period, all subjects
were required to visit the hospital every 4 weeks
to receive behavioral therapy for obesity based on
the LEARN program developed by Brownell.12
Under the program, subjects were counseled on
how to modify their behavior and diet (based on
a 1500 kcal/day allowance) and how to increase
their overall exercise. Compliance with the guide-
lines was assessed at each of these visits. Any side
effects that subjects had felt during medication
were to be reported to the researchers at every
visit.
Body weight, waist circumference, and blood
pressure were measured at the outset and at every
subsequent visit. Height was determined prior to
commencing study medication. Height was mea-
sured to the nearest to 0.1 cm, and weight to the
nearest to 0.1 kg with the subjects wearing light
clothing and with an empty stomach. Body mass
index was calculated as weight in kilograms
divided by the square of the height in meters.
Waist size was measured to the nearest to 0.5 cm
by the same person following the instructions
suggested by NIH.13 Concentration of total cho-
lesterol, HDL-cholesterol, LDL-cholesterol, trigly-
ceride in serum, fasting plasma glucose, high-sen-
sitive CRP and uric acid levels were determined
prior to commencing study medication and at
endpoint.
The most valuable consideration in evaluating
the efficacy is the change in body weight and
waist circumference before and after the treatment
in the intention-to-treat (ITT) population. Another
weight-related criterion was the proportion of
patients who lost 5% or more weight and 10% or
more weight than the baseline weight. Changes in
the level of cholesterol, triglycerides, HDL and
LDL, high-sensitive CRP, uric acid and blood
pressure were assessed as secondary variables.
In addition, for safety assessment, chest X-ray
and ECG of each subject were taken, and thyroid
stimulation hormone level was determined prior
to commencing study medication, and standard
laboratory tests (hematology, blood chemistry)
were done prior to the commencement of study
medication, and at endpoint.
Statistical analysis
All statistical analyses used statistical analysis
system (SAS) for Window (version 8.01).
For the change of anthropometric measurement
values and blood pressure, analysis was made in
the ITT population using the last observation
carried forward method. T-test was performed to
test a statistical significance of mean differences in
this analysis.
For the laboratory test results, analysis was
done in the completer population. Because the
sample size was too small for normal distribution,
nonparametric methods were used. Wilcoxon's
rank sum test was used to compare characteristics
between phentermine group and placebo group.
Wilcoxon's signed rank test was used to assess
changes in variables in subjects after the treatment.
For the difference of the occurrence rate of
adverse events between the two groups, only
those symptoms which had occurred in at least
more than 5% of subjects in any group among all
abnormal reported symptoms were analyzed.
However, adverse events complained in initial
run-in period were removed from the analysis. All
other complaints in ITT population were included
in adverse event analysis. In addition, one subject
who reported that she wishes to discontinue the
study participation on the 4th week of medication
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due to the side effect was included in adverse
event analysis. For the analysis of side effects, chi-
square test was used in principle. In the case of
very small number of cell count, Fisher's exact test
was used. All statistical tests were two-sided at
the 5% significance level.
RESULTS
In total, 94 men and women have displayed
intention to participate in the study. 15 of them
were eliminated as they violated the initial instruc-
tion during screening period, and 11 were elimi-
nated as they fell in with the exclusion criteria.
Actual number of participation subjects was 68,
and 13 men and 55 women were randomly
assigned to double-blind treatment. 35 were ran-
domized to phentermine group, and 33 to placebo
group. 36 of 68 (52.9%) had completed the 14-
week treatment course. 24 of 35 phentermine group
(68.6%), and 12 of 33 (36.4%) had completed the
study.
At baseline, there was no significant difference
Table 1. Baseline Characteristics
Phentermine (n = 35) Placebo (n = 33)
Age (yrs)* 34.74 ± 8.54 31.97 ± 8.05
Female (%) 28 (80.0%) 27 (81.8%)
Weight (kg)* 76.42 ± 10.25 77.41 ± 10.40
Body mass index (kg/m2)* 29.29 ± 3.05 29.42 ± 2.91
Waist (cm)* 92.79 ± 6.39 92.29 ± 8.01
Systolic BP (mmHg)* 125.37 ± 11.36 125.85 ± 13.26
Diastolic BP (mmHg)* 79.70 ± 9.17 82.45 ± 10.02
Smoking (current smokers) 10 (28.6%) 6 (18.2%)
*Data are mean ± SD.
Data are number (%).
Table 2. Changes in Body Weight, Waist Circumference, and Blood Pressure in Intention-To-Treat Population
Phentermine (n = 28) Placebo (n = 24) p value
Weight (kg) Baseline 77.7 ± 11.0 77.8 ± 11.5
14th week 70.5 ± 11.1 75.9 ± 12.1
Change -7.2 ± 2.7 -1.9 ± 2.7 < 0.001*
Waist (cm) Baseline 93.0 ± 6.4 91.9 ± 8.4
14th week 85.8 ± 7.6 89.9 ± 8.7
Change -7.2 ± 3.1 -2.0 ± 4.0 < 0.001*
SBP (mmHg) Baseline 126.3 ± 11.4 123.4 ± 13.7
14th week 124.3 ± 12.6 127.3 ± 10.0
Change -2.0 ± 12.0 3.9 ± 11.8 0.081*
DBP (mmHg) Baseline 79.6 ± 8.5 78.1 ± 8.1
14th week 83.3 ± 11.0 84.4 ± 9.7
Change 3.7 ± 9.3 6.3 ± 8.1 0.296*
*Student's t-test.
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between the groups in terms of age, sex, weight,
waist, blood pressure, and smoking rate (Table 1).
During the two-week run-in period, the mean
decrease in weight was 0.58 (SD 1.18) kg, and that
of BMI was 0.22 (SD 0.46) kg/m2, with the asso-
ciated reduction of 1.20 (SD 3.19) cm in waist cir-
cumferences across both groups.
In the analysis of the ITT population, there was
a statistically significantly greater mean reduction
in both body weight and waist circumference in
phentermine- treated subjects to subjects in pla-
cebo group (p <0.001) (Fig. 1, Table 2). There was
no significant difference in blood pressure change
between the two groups after the treatment.
Table 3 shows the result in completers. In the
analysis of completers, there was also a statisti-
cally significantly greater mean reduction in both
body weight and waist circumference in phenter-
mine-treated subjects to subjects in placebo group
(p < 0.001) (Table 3). Including the weight reduc-
tion of the run-in period, placebo group shows
about 2 - 3 kg of weight reduction and phenter-
mine group shows about 7 kg of weight reduction
(Table 2, 3). Run-in period subtracted analysis
showed that phentermine HCl 37.5 mg was
associated with significant weight reduction (-7.1
[SD 2.4] kg for completers and -6.7 [SD 2.5] kg for
ITT) and shortening of waist circumference (-6.9
[SD 3.3] cm for completers and -6.2 [SD 3.5] cm for
ITT; data not shown in table; all p < 0.001).
In the analysis of both ITT and completers, a
significantly greater proportion of patients in the
phentermine group achieved weight reduction of
5% or greater from the baseline compared with
the placebo group, and it was same for the
subjects who lost 10% or more weight from
baseline (Fig. 2).
In completers, the changes of blood pressure,
lipid levels, fasting plasma glucose, high-sensitive
CRP and uric acid from baseline to endpoints are
shown in Table 3. There was no statistically signi-
ficant difference between the groups in these
variables except total cholesterol. After the treat-
ment, the mean change of total cholesterol in
phentermine group was -7.8 (SD 28.5) mg/dL,
compared to 10.7 (SD 20.2) mg/dL in placebo
group. The changes from baseline to endpoints in
each group were not significantly different from
zero. However, the difference between groups
was significant (p = 0.048, Table 3).
In addition, the change of non-HDL-cholesterol
between groups was also significant (data not
shown in table, p = 0.023 by Wilcoxon rank sum
test). The mean change of non-HDL-cholesterol in
phentermine group was -9.7 (SD 24.8) mg/dL,
while the mean change in placebo group was 7.8
(SD 24.8) mg/dL. However, the changes in each
group were not significant, same as total choles-
terol.
The proportion of patients who had reported
Fig. 1. Change from baseline in body weight (A) and waist circumference (B). Data are mean (SE) values for the full
intention-to-treat population with the last observations carried forward. p < 0.001 for phentermine vs. placebo in body
weight and waist circumference.
(A) (B)
Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People
Yonsei Med J Vol. 47, No. 5, 2006
any side effect was higher than that of patients
who had not reported. Table 4 provides an an-
alysis of all the adverse events occurred in at
least 5% of patients in any group. The adverse
events in Table 4 are listed in the frequency
order of phentermine group. The number of
subjects who had reported any adverse events in
phentermine group was significantly larger than
that in placebo group. However, the reported
rate of adverse events in placebo group was even
with 75% (18/24). Among all reported adverse
events, dry mouth and insomnia are the events
which occurred significantly more frequently in
phentermine group. The occurrence rates of the
other adverse events were not significantly dif-
ferent between the groups. For the most part,
these events were mild to moderate in intensity,
and only a few cases needed to reduce the
dosage.
There were two subjects who withdrew due to
adverse events. One of them withdrew because of
dry mouth and foreign body sensation in throat.
The other withdrew due to nausea and headache.
Another two subjects complained severe adverse
symptoms. One complained of severe headache,
and the other, of severe headache and nausea.
However, after reducing dosage by half, their
symptoms had improved much or totally removed,
and both of them had succeeded in completing
the study. All four were included in phentermine
group.
The discontinuation rate was significantly
higher in placebo group (p = 0.008), and there
was significant difference in the mean duration
of study participation between two groups, 11.0
(SD 4.9) weeks for phentermine group vs. 8.2 (SD
5.3) weeks for placebo group (p = 0.030). In phen-
termine group, 11 of 35 (31.4%) withdrew after
run-in period. Seven of them discontinued study
participation without any clear reason, and two
of them discontinued because of adverse events.
One subject withdrew due to no weight losing
effect of the drug. There was one subject who
discontinued due to the difficulty in following
the behavioral guideline. In placebo group, 21 of
33 (63.6%) withdrew after run-in period. 15 of
them discontinued study participation without
any clear reason. There was nobody who with-
drew because of adverse events. Five was due to
Fig. 2. Proportion of patients who lost 5% and
10% of baseline weight at 14th week. ITT, intention-
to-treat.
Table 3. Changes in Anthropometric Values and Cardiovascular Risk Factors in Patients Who Completed 14 Weeks
Follow-up
Phentermine (n = 24) Placebo (n = 12) p value
Weight (kg) Baseline 78.0 ± 11.5 77.4 ± 9.4
14th week 70.5 ± 11.8 74.3 ± 10.5
Change -7.5 ± 2.7 -3.1 ± 3.2 < 0.001
Waist (cm) Baseline 93.1 ± 6.8 91.1 ± 8.0
14th week 85.8 ± 8.1 87.8 ± 7.3
Change -7.3 ± 3.3 -3.3 ± 4.7 < 0.001
SBP (mmHg) Baseline 126.9 ± 12.1 129.0 ± 13.0
14th week 123.8 ± 13.5 131.2 ± 9.5
Change -3.1 ± 12.5 2.2 ± 8.5 0.122*
DBP (mmHg) Baseline 79.4 ± 7.8 80.5 ± 6.4
14th week 83.5 ± 11.7 87.8 ± 9.9
Change 4.1 ± 9.0 7.3 ± 8.1 0.219*
Fasting glucose (mg/dL) Baseline 89.2 ± 9.9 92.3 ± 7.7
14th week 88.0 ± 9.8 87.1 ± 7.6
Change -1.2 ± 10.1 -5.2 ± 5.7 0.163*
Total-C (mg/dL) Baseline 183.0 ± 32.1 166.8 ± 18.9
14th week 175.2 ± 32.7 177.4 ± 25.9
Change -7.8 ± 28.5 10.7 ± 20.2 0.048*
TG (mg/dL) Baseline 120.3 ± 54.6 148.7 ± 96.5
14th week 89.3 ± 41.1 164.4 ± 293.0
Change -31.0 ± 45.2 15.8 ± 239.1 0.907*
HDL-C (mg/dL) Baseline 52.0 ± 14.2 52.9 ± 14.4
14th week 53.9 ± 12.5 55.8 ± 15.1
Change 1.9 ± 7.8 2.9 ± 8.8 0.840*
LDL-C (mg/dL) Baseline 116.5 ± 31.9 92.8 ± 12.7
14th week 115.7 ± 30.4 107.2 ± 22.0
Change -0.8 ± 28.5 14.4 ± 22.2 0.058*
hsCRP (mg/dL) Baseline 2.18 ± 2.76 0.59 ± 0.44
14th week 1.38 ± 1.79 0.95 ± 1.17
Change -0.79 ± 3.14 0.36 ± 1.35 0.203*
Uric acid (mg/dL) Baseline 5.01 ± 1.65 4.78 ± 1.29
14th week 4.89 ± 1.59 5.31 ± 1.94
Change -0.13 ± 0.74 0.53 ± 1.11 0.062*
*By Wilcoxon rank sum test.
By Student's t-test.
Number of phentermine group = 21.
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personal schedule, and one due to no weight
losing effect of the drug. Among 114 reports of
total adverse events in subjects who were treated
for more than 6 weeks, only 31 (27.2%) had newly
occurred after the 6th week of treatment, and 24
(21.1%) symptoms had prolonged for more than
4 weeks. In phentermine group, 13 of 29 had
reported the occurrence of adverse events after
the 6th week of treatment, and in placebo group,
4 of 24 had reported after the 6th week.
In completers, there was no significant differ-
ence of change of level from baseline to endpoints
in RBC, WBC, and platelet counts, hemoglobin,
hematocrit, BUN, creatinine, total bilirubin, AST
and ALT levels.
DISCUSSION
Generally, currently recommended obesity treat-
ment method is the improvement of life style, the
essentially featuring reduction of calorie intake
and increasing physical activity. However, the
outcome of such method have shown to be dis-
appointing. Therefore, several drugs have been
developed for weight reduction, and a few of
them had been approved for obesity treatment.
Phentermine is one of these drugs. It is a drug
which had been approved by US FDA in 1959
with a brand name of Ionamin , and more than
50 million prescriptions of which have been
written out since 1960. Despite its wide usage, few
clinical trials of phentermine for the weight
Table 4. Patients Reporting Adverse Events ( 5% in Any Treatment Group)
Phentermine (n = 29)* Placebo (n = 24) p value
Any adverse event 28 (96.6) 18 (75.0) 0.021
Dry mouth 16 (55.2) 4 (16.7) 0.004
Insomnia 10 (34.5) 0 (0.0) 0.001
Headache 8 (27.6) 3 (12.5) 0.178
Dizziness 8 (27.6) 3 (12.5) 0.178
Fatigue 7 (24.1) 3 (12.5) 0.281
Palpitation 6 (20.7) 2 ( 8.3) 0.211
Nausea 5 (17.2) 6 (25.0) 0.488
Flushing 4 (13.8) 0 (0.0) 0.117
Constipation 4 (13.8) 2 (8.3) 0.678
Indigestion 4 (13.8) 3 (12.5) 1.000
Back pain 3 (10.3) 0 (0.0) 0.242
Epigastric pain 3 (10.3) 0 (0.0) 0.242
Chest discomfortness 3 (10.3) 1 (4.2) 0.617
Mood change 3 (10.3) 2 (8.3) 1.000
Skin problem 2 (6.9) 0 (0.0) 0.495
Sweating 2 (6.9) 0 (0.0) 0.495
Foreign body sensation of throat 2 (6.9) 0 (0.0) 0.495
Anxiety 2 (6.9) 2 (8.3) 1.000
*A patient who had been withdrawn due to adverse events without clinic visit is included.
By Chi-square test.
By Fisher's exact test.
Kyoung Kon Kim, et al.
Yonsei Med J Vol. 47, No. 5, 2006
reducing effect and safety have been performed in
Korea. Phentermine is produced in two major
forms. One is phentermine resin (eg. Ionamin )
and the other is phentermine-HCl (eg. Adipex ),
where the latter is released more rapidly.
Cost is an important factor in the pharma-
cologic therapy of obesity. The difference of cost-
effectiveness between sibutramine and phenter-
mine in US has already been described in
introduction, which is guite the same in Korea.
Moreover, obesity treatment is not covered by
medical insurance in Korea until present in 2006.
Therefore, total drug purchasing expense for
obesity treatment is burdened to patients. Until
2006, Reductil and Xenical are the only drugs
approved for long-term treatment of obesity in
Korea. Both of these drugs are expensive. Pur-
chasing cost for 1 month as initial recommended
dosage is over 100,000 won in 2006. However, the
price for the use of phentermines is around one
fourth of the price for using Reductil or Xenical
. Relatively lower cost of phentermine maybe of
assistance for those patients who have difficulty in
purchasing highly priced obesity drugs.
In this study, 2 weeks run-in period and 12
weeks administration of phentermine-HCl 37.5 mg
had induced clinically significant weight reduc-
tion, shortening of waist circumference, and
reduction of total cholesterol and non-HDL-
cholesterol level. This result would reduce the risk
of cardiovascular disease in the ultimate. More-
over, over 80% of subjects of phentermine group
lost 5% or more of initial weight and more than
half subjects lost 10% or more. This shows us that
most of obese patients can obtain the conventional
goal of obesity treatment by short-term use of
phentermine.
There have been many reports about the weight
reduction effect of phentermine until today. In
1968, Munro et al.14 performed long-term double
blind placebo-controlled study on 108 obese
women with phentermine resin. They compared
three groups of placebo, continuous phentermine
therapy and intermittent phentermine therapy
(administration of phentermine and placebo every
4 weeks, alternatively) for 36 weeks, and reported
that both continuous therapy (mean weight loss
12.2 kg) and intermittent therapy (13.0 kg) resulted
in significant weight reduction than placebo (4.8
kg, p < 0.001). In this study, they reported that
phentermine had held the effect of gradual loss in
weight even after the 6 months of drug admin-
istration, which is different to other weight-losing
drugs Langlois et al.15 performed placebo-con-
trolled study on 59 patients with phentermine
hydrochloride for 22 weeks (the duration of drug
administration was 14 weeks) in 1968. In this
study, phentermine group (mean weight loss 16.1
kg) showed significantly more weight loss than
placebo (3.9 kg, p < 0.001). In both studies, experi-
ments reported that side effects were not serious.
Weintraub et al.7 reported the result of placebo
controlled study in which they compared the
effect of phentermine resin 30 mg, fenfluramine
hydrochloride 60 mg and phen-fen (phentermine
resin 15 mg + fenfluramine hydrochloride 30 mg)
on 81 subjects for 24 weeks in 1984. In this result,
phentermine group (mean weight loss 10.0 kg),
fenfluramine group (7.5 kg), and phen-fen group
(8.4 kg) showed significantly superior weight
reduction effect than placebo. However, phenter-
mine only group induced more side effects than
phen-fen combination therapy or placebo. In
addition to these studies, there had been several
other small sized clinical trials using phentermine,
however, all of them showed similar weight
reduction effect, and reported similar side effect
profiles which could be mimicked with by
subjects in general.
Desirably, the process of weight reduction
should be taken gradually and continue for a long
time. However, this is difficult. Therefore, the
intentional weight losing process should be
divided into two periods, initial weight reduction
period and sustaining reduced weight period. The
guideline of US National Institutes of Health16
recommends that the target weight which is 10%
or more less than initial weight should be gained
over 6 months, and then the patient should
attempt to maintain it. It is because, after certain
amount of weight reduction, it becomes very
difficult to lose more weight due to several
adaptation processes to reduced weight such as
decreased basal metabolic rate. In our study,
phentermine group gained 7.2 kg of weight loss
on average for 14 weeks, and this amount of
reduced weight is 9.3% of initial weight. The
result of our study shows that phentermine can
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induce initial target weight, even though the
clinical trial of long-term usage of phentermine is
needed.
Phentermine is classified as sympathetic amine,
which shows its effect by the secretion of norepi-
nephrine at nerve terminal. However, the exact
appetite suppressing mechanism of phentermine
is not fully understood. Several studies on this
topic suggest that phentermine may suppress
appetite on hypothalamus by the increase of the
concentration of norepinephrine,17 dopamine18,19
and serotonin20 in CNS. Phentermine usually in-
duce tachycardia and increase blood pressure
because of its sympathomimetic effect. In this
study, pulse rate had not regularly checked on
every visit. However, in adverse events analysis,
only 6 of 29 (20.7%) phentermine group subjects
complaint on their palpitation, and this number is
not significantly more than placebo group. Simi-
larly, blood pressure had not increased after
treatment period in phentermine group, and there
had been no significant difference between both
groups. Not only the blood pressure of endpoints
but also the blood pressure of 4 weeks administra-
tion of phentermine is not significantly different
between two groups. Not shown in the results, the
analysis of blood pressure at 6th week, i.e. after
4 weeks administration of phentermine, the mean
systolic pressure was 127.4 (SD 10.2) mmHg and
the mean diastolic pressure was 85.1 (SD 8.4)
mmHg in phentermine group (n = 28), compared
to systolic 127.3 (SD 12.7) mmHg and diastolic
83.5 (SD 10.4) mmHg in placebo group (n = 24).
Therefore, we can suggest that the administration
of phentermine would not induce any serious
cardiovascular effect at least for the patients
whose risk of cardiovascular disease is not high.
In our study, the administration of phentermine
caused just a few serious adverse events. In
completers, no subjects showed abnormal result
on standard laboratory test. Although the number
of subjects who had reported adverse events was
much larger than that of subjects without adverse
events, and more subjects in phentermine group
complained on side effects than subjects in
placebo group, dry mouth and insomnia were the
only adverse events that occurred significantly
more frequently in phentermine group. Moreover,
these events were not so serious as to prevent the
subjects from participating in the study. Drinking
plenty of water could reduce dry mouth symptom
and in most cases, it resolved of itself. 5 of 28
phentermine completers reported that they had
experience dry mouth during the whole period of
phentermine administration. There was nobody
who reported that their insomnia prolonged over
4 weeks. In many cases of insomnia, by switching
the administration time to the morning the
symptom could be improved.
According to the direction of Gate pharmaceu-
ticals which is one of drug companies producing
phentermine drugs, known adverse effects of
phentermine are primary pulmonary hyperten-
sion, valvular heart disease, palpitation, tachy-
cardia, elevated blood pressure, hypersensitivity,
dizziness, insomnia, mood change, tremor,
headache, driness of the mouth, unpleasant taste,
diarrhea, urticaria, impotence, and changes in
libido, etc.21 At the initial briefing on the research
procedure to the subjects, the possibility and
symptoms of primary pulmonary hypertension
and valvular heart disease were informed and the
subjects had been instructed to notify to the re-
searchers immediately if they had felt related
symptoms. However, there had been no report of
symptoms related to these two serious adverse
events in the study period. The majority of other
known adverse effects had been reported in the
study. For taste change, there was one report in
placebo group and the symptom was minimal and
self-limited. There was no report of taste change
in phentermine group. There was no report of
tremor and diarrhea in both groups. There had
been no definite report of urticaria. However, one
subject reported minimal temporary itching sensa-
tion at the 10th week in phentermine group, and
another reported temporary skin lesion on face at
the 6th week which could not been identified by
researchers because of complete recovery on the
subsequent clinical visit. There had been no report
on impotence and change of sexual desire, and
this might be due to the self report method of side
effects whichever they felt during study participa-
tion, not the selection method on side effects list.
There had been seven reports about epigastric
pain and chest discomfort. After detailed history
taking and physical examination, all of these
reports had been considered to be not related to
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cardiac problems, and therefore no further diag-
nostic study had been performed. In the study,
the subjects were relatively healthy obese people;
the age of the subjects was not high and there had
been no subjects with hypertension and diabetes
mellitus, both of which are strong risk factors of
cardiovascular disease. Only 23.5% of subjects
were smokers, and the rate was relatively lower
than known average smoking rate amongst
Korean. It might be due to the female abundance
of the subjects. Therefore, the possibility of
cardiovascular disease in this study group might
be much lower than that of average Korean obese
population. In real practice of obese patient with
administration of phentermine, the health pro-
vider should pay attention to the symptoms of
epigastric pain or chest discomfort especially with
the high risk patients with cardiovascular disease.
Then, again, further evaluation on the cardiac
related symptoms could be performed even
though for the case of non cardiac disease. Such
aspect of phentermine administration might be
the limitation of usage on the obese patients with
high age, diabetes mellitus, or past medical his-
tory of cardiovascular disease.
Phentermine is classified by US Drug Enforce-
ment Agency (DEA) as schedule IV drug.22 The
completers had been requested to visit the
researchers at the 18th week for the check up of
withdrawal symptoms or other unexpected ad-
verse events, at where they were provided with
laboratory results. 12 of 24 (50%) phentermine
completers and 6 of 12 (50%) placebo completers
visited researchers. There had been nobody who
complained withdrawal symptoms or other
adverse events.
Phentermine hydrochloride is indicated by US
FDA as a short-term (a few weeks) adjusted in a
regimen of weight reduction based on exercise,
behavioral modification and caloric restriction in
the management of exogenous obesity for patients
with an initial BMI 30 kg/m
2
, or 27 kg/m
2
in
the presence of other risk factors (e.g., hyper-
tension, diabetes, and hyperlipidemia). A short-
term is generally accepted as around three
months. Some experts insist that if the initial three
month effect on weight reduction is acceptable
good, the prolonged administration of phenter-
mine will be appropriate.23 This study is for the
evaluation of the effect and the safety of short-
term usage of phentermine. The clinical trials for
long-term effect and safety are also necessary.
Conclusively, we can suggest that short-term
phentermine administration can induce significant
weight reduction and the shortening of waist
circumference without clinically problematic ad-
verse events on relatively healthy obese people,
by this study.
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